Hims & Hers Health's 8.86% Plunge and 314th-Ranked $770M Volume as Shareholder Lawsuit Over Novo Nordisk Partnership Sparks Sell-Off

Market Snapshot

Hims & Hers Health (HIMS) closed with an 8.86% decline on March 20, 2026, marking one of the steeper single-day drops in the market. The stock traded at a volume of $0.77 billion, placing it at rank 314 in terms of trading activity for the day. The sharp selloff occurred amid ongoing legal uncertainties tied to a high-profile shareholder lawsuit, which has drawn significant investor attention.

Key Drivers

The stock’s decline coincided with a pivotal legal development involving Hims & Hers Health’s partnership with Novo Nordisk, the distributor of the weight-loss drug Wegovy. A California federal court is now considering a shareholder suit alleging that Hims exploited its collaboration with Novo Nordisk to market so-called “knockoff” drugs, capitalizing on the popularity of Wegovy. The lawsuit claims the company misrepresented the nature of its partnership, suggesting executives concealed risks that would ultimately lead to the collaboration’s collapse. This legal challenge has cast doubt on Hims’ business practices and transparency, triggering a sell-off as investors recalibrated their risk assessments.

Hims has responded by arguing that the lawsuit lacks merit, emphasizing that the plaintiff has not demonstrated that executives knew the partnership would fail. The company’s legal team contends that the allegations hinge on speculative claims rather than concrete evidence of intentional misconduct. By seeking dismissal of the case, Hims aims to mitigate reputational damage and reduce the financial and operational burden of prolonged litigation. However, the mere existence of the suit—along with the publicized defense strategy—has created short-term volatility, as investors weigh the potential for regulatory scrutiny or further legal complications.

The partnership with Novo Nordisk was initially seen as a strategic milestone for Hims, given Wegovy’s role in the booming weight-management sector. The alleged breakdown of this collaboration raises questions about the company’s ability to sustain high-margin partnerships in a competitive market. While Hims has not disclosed specific details about the partnership’s termination, the lawsuit’s focus on “knockoff” drugs suggests tensions over intellectual property or regulatory compliance. Such uncertainties could deter future partners, particularly in an industry where brand credibility and regulatory alignment are critical.

Market participants are also monitoring the broader implications for telehealth companies, which have faced heightened scrutiny over pricing strategies and product differentiation. The lawsuit against Hims could set a precedent for similar legal challenges, especially if courts rule that partnerships with pharmaceutical giants require stricter disclosure standards. For now, the stock’s performance reflects investor concerns over both the immediate legal risks and the long-term viability of Hims’ business model in an increasingly litigious environment.

The ongoing litigation underscores the fragility of Hims’ growth narrative, particularly as it navigates a post-pandemic market where telehealth valuations have become more sensitive to operational and reputational risks. While the company’s defense strategy may ultimately succeed in dismissing the case, the market’s reaction highlights how legal disputes—regardless of their eventual outcome—can disproportionately impact stock prices in high-growth sectors. For Hims, the path forward will depend on resolving this lawsuit efficiently while rebuilding investor confidence in its strategic partnerships and corporate governance.